Medicis sues Ranbaxy over generic - Phoenix Business Journal:

http://fountains-for-home.com/pool-pond-spitters.php
Medicis alleges Ranbaxy infringed on one or more claimsunder Medicis’ U.S. Patent 5,908,838 when it submitte an abbreviated new drug application for a genericc version of Solodyn tothe U.S. Food and Drug Administration. In its Medicis is requesting a permanent injunction preventing Ranbaxhy from infringing its patent by sellinb thegeneric version. Charles Caprariello, vice presidenyt of corporate communications and government affairs forRanbaxuy Inc. in Princeton, N.J., said the company has no commenty regarding theMedicis lawsuit. Patenyt litigation is not new to thegenerifc manufacturer. Last year about this time, Ranbaxy Laboratorie s Ltd. entered into an agreement withPfizer Inc.
to settl worldwide patent litigationinvolvinh Pfizer’s cholesterol-lowering medication Lipitor, which generated $12.78 billion in sales in 2007. The agreement allowed Ranbaxy to introduce a generifc version of the drug in November with 180 days of which means no other generic manufacturers can startg selling until 180 days afte that inthe U.S. Ranbaxy Laboratoriexs Ltd., India’s largest pharmaceutical company, settled a pateng infringement lawsuit with AstraZeneca inApril 2008.
AstraZeneca had filedf a patent infringement lawsuitg against Ranbaxy for trying to market a generid versionof AstraZeneca’s Esomeprazole magnesiumk capsules, Omeprazole tablets and Felodipinre capsules in the Unitefd States. Ranbaxy will be allowed to exclusivelyy sell its generic version of Nexium under a license from AstraZeneca onMay 27, 2014. Durinb the 180-day period following that Ranbaxy will distribute the only generifc Esomeprazole magnesium product inthe U.S. In November Ranbaxy reached an agreementwith Astellas/Boehringer Ingelheim to resolve paten t litigation involving Flomax capsules to treat benign prostatif hyperplasia.